

Fund Details

Classification	UCITS
ISIN	MT7000018750
Base Currency	EUR
Minimum Subscription	€0
Additional Subscription	1'000
NAV Frequency	daily
Inception Date	12/2010
NAV 29.05.2020	€
AUM	€ Mln.

Fees

Redemption & Subscription	0%
Management	€ p.a.
Performance	15% HWM

Main Structure

IM	Gamma Capital Markets
Company	Eiger Sicav Plc
PM	Carlo De Luca

Investment Objective

The Sub-Fund is invested with a global macro strategy and should be considered as a long term investment. The portfolio is composed of equities from the most well known American and pan-European companies (large cap and giant cap), with a globally acknowledged brand and strong fundamentals. All the companies composing the portfolio are leaders in their historical markets, with excellent growth potential in emerging countries where megatrends are ongoing, such as demographic growth, urbanization, infrastructures, technology etc. Portfolio volatility is contained through the choice of sectors and low correlated stocks.

Statistics

Standard Deviation	€
Max Drawdown	-12.7
Sharpe Ratio	2.7


Manager's Comment

Equity markets rebounded overall and gained significant returns, decreasing general volatility, as investors anticipated a partial reopening of the global economy. Macroeconomic data continue to suggest a weak economy: initial Jobless Claims in the United States have reached 10 million in the last month, bringing unemployment to 3.6% (compared to 3.5% expected); Q1 GDP growth was revised down to -5.0%, compared to the first estimate of -4.8%. To deal with serious problems, the FED quickly reacted by announcing a liquidity program that reaches 3 trillion. In response to the measures of the Central Bank and in full optimism regarding the partial openings of the global economies, the main equity indices recorded strong gains: in the last month, the S&P 500 climbed to end the month 4.8% higher and the NASDAQ by around 6.75%, in which growth stocks outperformed value stocks.

In this context, the revision to the "Biotech" strategy was carried out, supported by the entry of the titles most related to the discovery of the vaccine and the cure against Covid-19, and the titles were sold as per the revision of the "Best Brands" strategy. Currency hedging transactions on EUR/USD were carried out between 50 and 70% in the range between 1.08 and 1.09, hedging again at the break of the 1.10 level. In addition, the ISPY IM, ROBO IM and WTAI IM ETFs for long operations were purchased for long operations, maintaining the equity exposure on average around 43%, of which 33% is made up of the "Best Brands" strategy (securities linked to Megatrends), 5% from the "Biotech" strategy and 5% from the "Startech" strategy (big names in tech). In general, the sectors such as healthcare, basic necessities and utilities were the most resilient, accompanied by technological sectors driven by a greater need for remote interactions.

We currently remain cautious on equities, remaining invested between 50 and 60%, ready to reduce in the event of an increase in volatility. In the coming month, the new "Healthcare Revolution" strategy is likely to enter, with securities linked to healthcare and hospital sectors.

Sector's Allocation




Largest Position

XTracker Gold ETC Eur	4.2
ETFs Physical Gold	4.0
B 0 07/16/20	3.5
BUBILL 0 10/07/20	2.3
Gilead Sciences Inc	1.8
Amazon.com Inc	1.3
Regeneron Pharma	1.2
Netflix Inc	1.1
Adobe Inc	1.1
Nvidia Corp	0.9

Estimated Allocation

Primary Source of Fund Classification is Bloomberg



The Company 'Eiger SICAV' qualifies as a 'Maltese UCITS'

Eiger - Megatrend is a Sub-Fund of the Maltese SICAV Eiger Sicav Plc. Please carefully read the prospectus offer available on the website www.eigersicav.com and by any distributor, whose updated list you can find on the same website. This document is for information purposes only; it does not constitute an offer nor a solicitation to subscribe for securities on the basis of the same. The information does not constitute advice or personal recommendation concerning operations related to a specific financial instrument. Past performance is not indicative of future performance and there is no guarantee of Past performance for the future. Note that the returns shown are gross of taxes which may be payable in relation to the tax residence of the investor.